TARSUS PHARMACEUTICALS INC
(NASDAQ: TARS)
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis. The company was founded by Bobak Azamian and D. Michael Ackermann in 2017 and is headquartered in Irvine, CA.
36.250
+1.680
(+4.86%)
Range
- - 37.160
(-%)
Open
-
Previous Close
34.570
Bid Price
16.340
Bid Volume
9
Ask Price
16.900
Ask Volume
11
Volume
352,504
Value
-
Remark
View All Events
Loading Chart...
Please login to view stock data and analysis